EW - Edwards Lifesciences Corporation
| Previous Close | 137.13 |
| Open | 136.73 |
| Bid | 136.77 x 800 |
| Ask | 136.82 x 1000 |
| Day's Range | 134.56 - 137.14 |
| 52 Week Range | 100.20 - 156.87 |
| Volume | 694,710 |
| Avg. Volume | 1,213,648 |
| Market Cap | 28.663B |
| Beta | 0.72 |
| PE Ratio (TTM) | 44.96 |
| EPS (TTM) | 3.05 |
| Earnings Date | Oct 22, 2018 - Oct 26, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 156.00 |
Markit•4 days agoSee what the IHS Markit Score report has to say about Edwards Lifesciences Corp.
Edwards Lifesciences Corp NYSE:EW
Market Realist•8 days agoWhat to Expect for Boston Scientific in Fiscal 2018
During its Q2 2018 earnings release on July 25, Boston Scientific (BSX) updated its fiscal 2018 guidance. The company raised its fiscal 2018 sales guidance and maintained its adjusted EPS guidance at $1.37–$1.41, representing growth of 9%–12%.
- Thomson Reuters StreetEvents•9 days ago
Edited Transcript of EW earnings conference call or presentation 26-Jul-18 9:00pm GMT
Q2 2018 Edwards Lifesciences Corp Earnings Call
Market Realist•12 days agoBoston Scientific’s Q2 2018 Adjusted EPS Exceed Guidance
In the second quarter, Boston Scientific’s adjusted EPS grew 28% YoY (year-over-year) to $0.41, exceeding its guidance of $0.33–$0.35. Boston Scientific’s strong earnings growth in the quarter was due to its strong profit and loss metrics. The company is working on improving cost efficiencies through its end-to-end business by streamlining and automation initiatives, expanding global shared services, and leveraging global sourcing teams. Peers Abbott Laboratories (ABT), Edwards Lifesciences (EW), and Thermo Fisher Scientific (TMO) reported adjusted EPS growth of 17.7%, 30.5%, and 19. ...
- PR Newswire•13 days ago
Edwards Lifesciences To Present at 38th Annual Canaccord Genuity Growth Conference
IRVINE, Calif. , Aug. 2, 2018 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, is ...
Markit•13 days agoSee what the IHS Markit Score report has to say about Edwards Lifesciences Corp.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
Market Realist•14 days agoAbbott Laboratories’ Stock Price Performance in July
On July 24, Abbott Laboratories (ABT) ended the trading day at $64.40 per share. Currently, the stock is trading higher than its 50-day moving average of $62.45 and its 200-day moving average of $60.75.
Markit•18 days agoSee what the IHS Markit Score report has to say about Edwards Lifesciences Corp.
Edwards Lifesciences Corp NYSE:EW
Market Realist•19 days agoWall Street Raises Target Price on ABT after Strong Q2 Earnings
Abbott Laboratories' Q2 Results: What Drove Its Robust Growth?Analysts’ recommendations for ABT
- Zacks•19 days ago
Edwards Lifesciences (EW) Q2 Earnings Beat, Revenues Miss
Edwards Lifesciences (EW) gains from THVT strength on continued therapy adoption across all geographies in Q2.
Market Realist•19 days agoEW Fell 5.8% in After-Hours Trading despite Strong Q2 Results
EW Fell 5.8% in After-Hours Trading despite Strong Q2 ResultsEdwards Lifesciences reports its Q2 2018 earnings
- ACCESSWIRE•19 days ago
Free Stock Performance Review on Boston Scientific and Three Additional Medical Equipment Stocks
WallStEquities.com follows AxoGen Inc. (NASDAQ: AXGN), Boston Scientific Corp. (NYSE: BSX), Corindus Vascular Robotics Inc. (NYSE American: CVRS), and Edwards Lifesciences Corp. (NYSE: EW). Companies in the Medical Appliances and Equipment space are engaged in the manufacture of medical instruments, such as dental and surgical appliances.
- Associated Press•20 days ago
Edwards Lifesciences: 2Q Earnings Snapshot
On a per-share basis, the Irvine, California-based company said it had net income of $1.32. Earnings, adjusted for non-recurring gains, were $1.24 per share. The results surpassed Wall Street expectations. ...
- PR Newswire•20 days ago
Edwards Lifesciences Reports Second Quarter Results
IRVINE, Calif. , July 26, 2018 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today ...
- PR Newswire•21 days ago
Edwards Comments On CMS Advisory Panel
"Today's advisory panel meeting provided a review of current and possible future impacts of volume requirements on TAVR centers in the United States. In the absence of definitive evidence linking high volumes of procedures to high quality outcomes for TAVR patients, we continue to believe the best course of action is to focus on defined quality measures for both new programs and also those continuing to offer this life-saving, less-invasive therapy.
- Zacks•21 days ago
Medical Product Earnings Lineup for Jul 26: BAX, EW & More
Streak of regulatory developments and deep R&D focus are likely to drive the Medical Product industry this earnings season. Here we take a quick look at four Medical Product majors that are going to release earnings results.
- Market Realist•22 days ago
What to Expect from Edwards Lifesciences’ Q2 2018 Results
Edwards Lifesciences is slated to release its Q2 2018 earnings results on July 26 after the market closes. For Q1 2018, Edwards Lifesciences missed sales estimates. EW stock had fallen ~1.8% on April 24, when the company released its Q1 2018 earnings results.
InvestorPlace•23 days ago7 Healthcare Stocks That Are Coming to Life
U.S. equities continue to churn near major technical resistance levels — S&P 500 2,800 and 25,000 on the Dow Jones Industrial Average — as investors digest a heavy serving of headlines.
Markit•25 days agoSee what the IHS Markit Score report has to say about Edwards Lifesciences Corp.
This could indicate that investors who seek to profit from falling equity prices are not currently targeting EW. Over the last one-month, outflows of investor capital in ETFs holding EW totaled $729 million.
- Zacks•27 days ago
Will Edwards' (EW) Steady Overall Growth Drive Q2 Earnings?
Edwards Lifesciences (EW) expected to gain from strength in all business segments and geographies in Q2.
- Zacks•last month
Here's Why You Should Add Edwards Lifesciences (EW) Now
We are upbeat about Edwards Lifesciences' (EW) strong transcatheter valve sales in the domestic market as well as overseas.
- PR Newswire•last month
Edwards Lifesciences To Host Earnings Conference Call on July 26, 2018
IRVINE, Calif. , July 12, 2018 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, plans ...
Markit•last monthSee what the IHS Markit Score report has to say about Edwards Lifesciences Corp.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
- Investor's Business Daily•last month
Major Indexes Fall Broadly, Caterpillar Sells Off; These 2 Retailers Sink Especially Hard
The major indexes showed darker action with a broad decline Wednesday, but volume is mixed so far. Utilities advanced. Airlines fell hard.
- CNBC Videos•26 days ago
Opening Bell, July 20, 2018
Ringing today's opening bells are Edwards Lifesciences with Jen Hyde, patient advocate, celebrating its 60th anniversary of founding at the NYSE, and Discovery Inc. with Luke Tipple, TV host and marine biologist, celebrating Shark Week 2018 at the Nasd...
